Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRP104 in children with ADHD
NCT00556296Phase 3Completed
- Sponsor
- New River Pharmaceuticals
- Start
- Oct 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by New River Pharmaceuticals. Primary endpoint: Change score from baseline of the ADHD Rating Scale at 4 weeks. Started Oct 2004; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00556296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556296.